It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And the company did it with a big assist from some major league partners in the biopharma industry. Report
| Tuesday, April 29 | 11am ET, 8am PT | Presented by: Medpace
Realizing the potential of Risk Based Monitoring (RBM) requires coordination and collaboration across functions within both the Sponsor and CRO organizations. Dr. David Orloff and Dr. Alex Artyomenko will lead a discussion to explore the cross-functional perspectives and process alignment between Sponsor and CRO. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!